IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (Nasdaq: ALXN) concerning possible violations of federal securities laws.
If you purchased shares of Alexion and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
The investigation focuses on whether Alexion and certain of its officers and/or directors violated federal securities laws. Alexion announced that is investigating accusations of improper sales practices of its top drug, Soliris, which is estimated to account for 92% of the Company’s $3.1 billion in sales for 2016. The Company retained outside counsel and announced its decision to delay its third-quarter financial report.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.